{"id":"stem-and-progenitor-cells","safety":{"commonSideEffects":[{"rate":"null","effect":"Infection"},{"rate":"null","effect":"Graft-versus-host disease"}]},"_chembl":{"chemblId":"CHEMBL5315110","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Stem and progenitor cells have the ability to differentiate into various cell types, allowing them to repair or replace damaged tissues and cells. This process can be used to treat a range of conditions, including those affecting the heart, brain, and other organs.","oneSentence":"Stem and progenitor cells are used to repair or replace damaged tissues and cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:27.241Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of heart failure"},{"name":"Treatment of stroke"}]},"trialDetails":[{"nctId":"NCT00128960","phase":"","title":"Quality of Life in Patients Who Have Undergone Stem Cell Transplant","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2005-08-11","conditions":"Long Term Psychological Affects on HSCT","enrollment":173},{"nctId":"NCT07495176","phase":"NA","title":"USC-Exos in Corpus Spongiosum Reconstruction for Hypospadias","status":"COMPLETED","sponsor":"Shanghai Children's Hospital","startDate":"2021-02-01","conditions":"Hypospadias","enrollment":82},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT01306019","phase":"PHASE1, PHASE2","title":"Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-09-25","conditions":"X-linked Severe Combined Immunodeficiency (XSCID)","enrollment":40},{"nctId":"NCT07496372","phase":"PHASE3","title":"Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart Failure (NYHA Class III-IV)","status":"NOT_YET_RECRUITING","sponsor":"Help Therapeutics","startDate":"2026-04-30","conditions":"Heart Failure","enrollment":80},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT07498218","phase":"PHASE1","title":"Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue","status":"NOT_YET_RECRUITING","sponsor":"Ayu, Inc.","startDate":"2026-03-02","conditions":"Diabetic Foot Ulcer (DFU), Granulation of Chronic Diabetic Wounds","enrollment":24},{"nctId":"NCT05909202","phase":"NA","title":"A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2024-06-05","conditions":"Neoplasm, Caregivers","enrollment":218},{"nctId":"NCT06954987","phase":"PHASE2","title":"Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-17","conditions":"Acute Myeloid Leukemia","enrollment":244},{"nctId":"NCT00001405","phase":"","title":"Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1994-02-27","conditions":"Granuloma, Granulomatous Disease, Chronic, Leukocyte Disease","enrollment":850},{"nctId":"NCT06321198","phase":"NA","title":"A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-02-10","conditions":"Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)","enrollment":12},{"nctId":"NCT07020533","phase":"PHASE1","title":"A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-05-08","conditions":"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":46},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT06905834","phase":"PHASE2","title":"Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments","status":"NOT_YET_RECRUITING","sponsor":"Instituto de Investigación Biomédica de Salamanca","startDate":"2026-05","conditions":"Dry Eye Disease (DED), Graft-Versus-Host Disease(GVHD)","enrollment":30},{"nctId":"NCT01176006","phase":"PHASE2","title":"Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-05","conditions":"DOCK8 Deficiency","enrollment":70},{"nctId":"NCT07012044","phase":"PHASE1","title":"A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-30","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT05071222","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-19","conditions":"Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency","enrollment":7},{"nctId":"NCT01087294","phase":"PHASE1","title":"Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-08-04","conditions":"Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins","enrollment":85},{"nctId":"NCT05665166","phase":"PHASE1, PHASE2","title":"Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Manchester","startDate":"2023-06-01","conditions":"Mucopolysaccharidosis II","enrollment":5},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT05554419","phase":"PHASE2","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-01","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm","enrollment":184},{"nctId":"NCT06959771","phase":"PHASE1, PHASE2","title":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-16","conditions":"CD40L-HyperIgM Syndrome","enrollment":1},{"nctId":"NCT04214249","phase":"PHASE2","title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-17","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":49},{"nctId":"NCT05463133","phase":"PHASE1, PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":"Chronic Granulomatous Disease","enrollment":50},{"nctId":"NCT05896163","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-08-30","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":30},{"nctId":"NCT05531786","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-06","conditions":"Graft vs Host Disease","enrollment":50},{"nctId":"NCT01303146","phase":"PHASE2","title":"Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-10","conditions":"Metachromatic Leukodystrophy","enrollment":1},{"nctId":"NCT05139056","phase":"PHASE1","title":"Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2023-05-02","conditions":"Currently Only Enrolling Glioblastoma Patients at First Recurrence","enrollment":36},{"nctId":"NCT01212055","phase":"","title":"Apheresis of Patients With Immunodeficiency","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-08","conditions":"LAD-1, DOCK8, GATA2 Deficancy","enrollment":7},{"nctId":"NCT03173937","phase":"PHASE1, PHASE2","title":"Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2017-06-13","conditions":"Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)","enrollment":37},{"nctId":"NCT00001529","phase":"","title":"Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1996-03-18","conditions":"Graft-Versus-Host Disease, Graft-versus-leukemia, Donor Apheresis","enrollment":500},{"nctId":"NCT07498465","phase":"PHASE1","title":"A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-09-10","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia","enrollment":29},{"nctId":"NCT05722210","phase":"","title":"Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2026-04-01","conditions":"Hematopoietic Stem Cell Transplant","enrollment":500},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT04975698","phase":"PHASE2","title":"HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2021-10-25","conditions":"HIV Associated Lymphoma","enrollment":12},{"nctId":"NCT05243797","phase":"PHASE3","title":"Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation","status":"RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2022-09-08","conditions":"Multiple Myeloma","enrollment":1594},{"nctId":"NCT06687837","phase":"PHASE1","title":"Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons","status":"RECRUITING","sponsor":"Jeffrey S. Schweitzer, MD, PhD","startDate":"2025-04-29","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT06209190","phase":"NA","title":"Safety and Feasibility of TMLI as Conditioning Regimen in Allogeneic Hematopoietic Stem-cell Transplantation","status":"COMPLETED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2023-09-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":14},{"nctId":"NCT05246813","phase":"","title":"Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)","status":"RECRUITING","sponsor":"Imelda Hospital, Bonheiden","startDate":"2022-02-11","conditions":"Osteoporosis, Osteoarthritis, Hip, Hip Fractures","enrollment":24},{"nctId":"NCT07493408","phase":"PHASE2","title":"Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-30","conditions":"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia, Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)","enrollment":45},{"nctId":"NCT04208529","phase":"PHASE3","title":"A Long-term Follow-up Study in Participants Who Received CTX001","status":"ENROLLING_BY_INVITATION","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2021-01-20","conditions":"Beta-Thalassemia, Thalassemia, Sickle Cell Disease","enrollment":160},{"nctId":"NCT07492966","phase":"","title":"Exosomes Effect on Visual Function in CVI","status":"COMPLETED","sponsor":"Hatice Semrin Timlioglu İper","startDate":"2024-06-30","conditions":"Cortical Visual Impairment, Visual Function","enrollment":32},{"nctId":"NCT07483385","phase":"NA","title":"Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"The General Hospital of Western Theater Command","startDate":"2026-01-13","conditions":"Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation, Hematologic Disorders","enrollment":45},{"nctId":"NCT07493538","phase":"PHASE2","title":"MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases","status":"NOT_YET_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2026-08","conditions":"AML, MDS, Acute Leukemia","enrollment":132},{"nctId":"NCT07404709","phase":"PHASE1, PHASE2","title":"Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2026-02-28","conditions":"Sudden Hearing Loss, Extracellular Vesicles","enrollment":9},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT06798623","phase":"PHASE1","title":"Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-03-24","conditions":"Anterior Cruciate Ligament Reconstruction","enrollment":15},{"nctId":"NCT03533816","phase":"PHASE1","title":"Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2020-01-31","conditions":"Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":38},{"nctId":"NCT06985498","phase":"PHASE2","title":"Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-01","conditions":"Acute Lymphobkastic Leukemia","enrollment":40},{"nctId":"NCT00092235","phase":"","title":"Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-26","conditions":"Chronic Graft vs. Host Disease","enrollment":650},{"nctId":"NCT00576979","phase":"PHASE1, PHASE2","title":"Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-03-04","conditions":"Leukemia","enrollment":51},{"nctId":"NCT07490392","phase":"","title":"Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantation in Prepubertal Age","status":"NOT_YET_RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2027-01-01","conditions":"Hematopoietic Stem Cells Transplantation, Pediatrics","enrollment":300},{"nctId":"NCT01453088","phase":"PHASE2","title":"Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-24","conditions":"Multiple Myeloma","enrollment":63},{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":"Systemic Sclerosis, Systemic Scleroses, Diffuse, Scleroderma","enrollment":60},{"nctId":"NCT07490288","phase":"NA","title":"Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"AML","enrollment":30},{"nctId":"NCT07489196","phase":"PHASE2","title":"A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major","status":"NOT_YET_RECRUITING","sponsor":"CorrectSequence Therapeutics Co., Ltd","startDate":"2026-04-05","conditions":"β-thalassemia Major","enrollment":20},{"nctId":"NCT02015013","phase":"PHASE2","title":"Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-15","conditions":"Idiopathic CD4-Positive, T-Lymphocytopenia","enrollment":40},{"nctId":"NCT04476901","phase":"PHASE2","title":"Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy","status":"RECRUITING","sponsor":"Joshua M Hare","startDate":"2021-05-07","conditions":"Non-ischemic Dilated Cardiomyopathy","enrollment":136},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":"Chronic Granulomatous Disease","enrollment":4},{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":"GATA2, Immunodeficiency, MDS","enrollment":144},{"nctId":"NCT00106925","phase":"","title":"Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2005-04-22","conditions":"Graft-versus-leukemia, Graft vs Host Disease, Graft Rejection","enrollment":1000},{"nctId":"NCT06576583","phase":"PHASE2","title":"Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators.","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-07-15","conditions":"Patellofemoral Osteoarthritis","enrollment":150},{"nctId":"NCT03949647","phase":"","title":"Collection of Bone Marrow Aspirate From Normal Volunteers","status":"RECRUITING","sponsor":"National Institute on Aging (NIA)","startDate":"2019-05-08","conditions":"Normal Aging","enrollment":2000},{"nctId":"NCT07488728","phase":"NA","title":"Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2025-10-01","conditions":"EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis, Letermovir","enrollment":80},{"nctId":"NCT07488663","phase":"NA","title":"MODELING OBSESSIVE COMPULSIVE DISORDER AND EXPLORING TREATMENT RESPONSE USING INNOVATIVE THERAPIES AND STEM CELLS","status":"ENROLLING_BY_INVITATION","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2023-04-30","conditions":"Obsessive - Compulsive Disorder","enrollment":60},{"nctId":"NCT04704648","phase":"NA","title":"Feasibility Study of Ocular Surface Squamous Neoplasia Surgical Excision in People Living With HIV in Sub-Saharan Africa","status":"RECRUITING","sponsor":"AIDS Malignancy Consortium","startDate":"2023-06-21","conditions":"Ocular Surface Squamous Neoplasia, HPV","enrollment":84},{"nctId":"NCT01890486","phase":"","title":"The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2001-05-21","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":2000},{"nctId":"NCT07214688","phase":"PHASE2","title":"Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2026-01-06","conditions":"Allogeneic Stem Cell Transplant Recipient","enrollment":209},{"nctId":"NCT05477563","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-08-02","conditions":"Beta-Thalassemia, Thalassemia, Hematologic Diseases","enrollment":26},{"nctId":"NCT02032004","phase":"PHASE3","title":"Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2014-03-03","conditions":"Chronic Heart Failure","enrollment":565},{"nctId":"NCT07487766","phase":"PHASE1, PHASE2","title":"The Safety and Efficacy of XytriX in the Treatment of Knee Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"TricelX Inc.","startDate":"2026-05","conditions":"Osteoarthritis","enrollment":50},{"nctId":"NCT07355868","phase":"EARLY_PHASE1","title":"Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy","status":"RECRUITING","sponsor":"Regend Therapeutics","startDate":"2026-03-19","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":12},{"nctId":"NCT06093867","phase":"","title":"Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2024-04-08","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":40},{"nctId":"NCT04680468","phase":"PHASE2","title":"Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-06-02","conditions":"Myeloma","enrollment":41},{"nctId":"NCT03267433","phase":"PHASE3","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2017-11-27","conditions":"Mantle Cell Lymphoma","enrollment":689},{"nctId":"NCT07487467","phase":"NA","title":"Autologous SVF Therapy for Type 2 Diabetes","status":"RECRUITING","sponsor":"Kaiser Clinic and Hospital","startDate":"2025-01-20","conditions":"Diabetes Mellitus, Type 2","enrollment":10},{"nctId":"NCT03570892","phase":"PHASE3","title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":"Non-Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT07485647","phase":"PHASE2","title":"Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing","status":"NOT_YET_RECRUITING","sponsor":"Eden Biltibo","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT07463651","phase":"PHASE3","title":"MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-05-01","conditions":"Acute Myeloid Leukemia (AML), FLT3-ITD Mutation, Allogeneic Hematopoietic Cell Transplantation (HCT)","enrollment":594},{"nctId":"NCT07485751","phase":"EARLY_PHASE1","title":"Safety and Feasibility of Nasal Delivery of Human Dental Follicle Mesenchymal Stem Cell-Derived Exosomes for Negative Symptoms in Treatment-Resistant Schizophrenia: A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Zigong Mental Health Center","startDate":"2026-03","conditions":"Schizophrenia Negative Type","enrollment":15},{"nctId":"NCT05405387","phase":"PHASE2","title":"Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-05-03","conditions":"Multiple Myeloma, Plasma Cell Leukemia","enrollment":120},{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT03328663","phase":"NA","title":"Psychological Intervention for Caregivers of Patients Undergoing Stem Cell Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-01-01","conditions":"Cancer","enrollment":100},{"nctId":"NCT04948463","phase":"PHASE4","title":"Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-11-15","conditions":"Febrile Neutropenia","enrollment":55},{"nctId":"NCT02257853","phase":"PHASE2","title":"Effectiveness of a Stress Reduction Intervention in Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2015-01-05","conditions":"Stress, Psychological, Caregivers","enrollment":53},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT04543591","phase":"PHASE3","title":"Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-12-10","conditions":"Thrombotic Microangiopathy","enrollment":148},{"nctId":"NCT07436650","phase":"NA","title":"Efficacy of High-Level Laser Therapy in Managing Oral Mucositis Among Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-06-15","conditions":"Oral Mucositis","enrollment":14},{"nctId":"NCT03180216","phase":"PHASE1","title":"T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's National Research Institute","startDate":"2017-02-15","conditions":"Viral Infections, Bone Marrow Transplant Infection","enrollment":32},{"nctId":"NCT07479043","phase":"PHASE3","title":"To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).","status":"NOT_YET_RECRUITING","sponsor":"Breathe Biologics, Inc.","startDate":"2026-07","conditions":"Acute Respiratory Distress Syndrome","enrollment":128},{"nctId":"NCT07048314","phase":"PHASE1, PHASE2","title":"Stem Cells for Erectile Dysfunction Post RALP","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-03-10","conditions":"Erectile Dysfunction, Prostate Cancer","enrollment":40},{"nctId":"NCT06541002","phase":"NA","title":"A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-01-27","conditions":"Sexual Dysfunction, Stem Cell Transplant Complications, Bone Marrow Transplant Complications","enrollment":300},{"nctId":"NCT05605574","phase":"NA","title":"Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":222},{"nctId":"NCT02789228","phase":"PHASE1","title":"Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's National Research Institute","startDate":"2016-10-12","conditions":"Solid Tumors","enrollment":28},{"nctId":"NCT04044365","phase":"","title":"Pediatric cGVHD Symptom Scale","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-02","conditions":"Graft vs Host Disease","enrollment":420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6660,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"stem and progenitor cells","genericName":"stem and progenitor cells","companyName":"Universitaire Ziekenhuizen KU Leuven","companyId":"universitaire-ziekenhuizen-ku-leuven","modality":"Biologic","firstApprovalDate":"","aiSummary":"Stem and progenitor cells are used to repair or replace damaged tissues and cells. Used for Treatment of heart failure, Treatment of stroke.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}